177Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and …
FE von Eyben, K Kairemo, C Paller, MA Hoffmann… - Biomedicines, 2021 - mdpi.com
In this systematic review and network meta-analysis (NMA), we aimed to assess the benefits
and harms of third-line (L3) treatments in randomized controlled trials (RCTs) of patients with …
and harms of third-line (L3) treatments in randomized controlled trials (RCTs) of patients with …
Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective …
S Igawa, T Ono, M Kasajima, M Ishihara… - Cancer Management …, 2019 - Taylor & Francis
Purpose: A T790M of the epidermal growth factor receptor (EGFR) is the most frequently
encountered mutation conferring acquired resistance to EGFR tyrosine kinase inhibitors …
encountered mutation conferring acquired resistance to EGFR tyrosine kinase inhibitors …
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
T Ono, S Igawa, S Kurahayashi, Y Okuma… - Investigational New …, 2020 - Springer
Background Exon 19 deletion and L858R point mutation in exon 21 of the epidermal growth
factor receptor (EGFR) are the most commonly encountered mutations in patients with non …
factor receptor (EGFR) are the most commonly encountered mutations in patients with non …
The relationship between short-term surrogate endpoint indicators and mPFS and mOS in clinical trials of malignant tumors: A Case study of approved molecular …
M Rui, Z Wang, Z Fei, Y Wu, Y Wang, L Sun… - Frontiers in …, 2022 - frontiersin.org
Objective: Due to the initiation of the priority review program in China, many antitumor drugs
have been approved for marketing based on phase II clinical trials and short-term surrogate …
have been approved for marketing based on phase II clinical trials and short-term surrogate …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PloS one, 2020 - journals.plos.org
Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
[HTML][HTML] The prognostic value of 18F-FDG PET/ct metabolic parameters in predicting treatment response before EGFR TKI treatment in patients with advanced lung …
N Agüloğlu, M Akyol, H Kömek… - Molecular Imaging and …, 2022 - ncbi.nlm.nih.gov
Objectives: This study makes a retrospective examination of exploring the prognostic value
of 18 fluorine-fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed …
of 18 fluorine-fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed …
Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice–results from the ElderTac study
WM Brueckl, HJ Achenbach, JH Ficker, W Schuette - BMC cancer, 2018 - Springer
Background In this prospective non-interventional study, the effectiveness and tolerability of
erlotinib in elderly patients with non-small-cell lung cancer (NSCLC) after≥ 1 platinum …
erlotinib in elderly patients with non-small-cell lung cancer (NSCLC) after≥ 1 platinum …
Efficacy of icotinib, an EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients with exon 19 deletion and exon 21 L858R: a retrospective analysis in …
Y Wang, X Yuan, M Yang, Z Shen, H Chen, X He, Y Ma… - Pharmacology, 2021 - karger.com
Introduction: The effect of icotinib on non-small cell lung cancer (NSCLC) patients with
EGFR exon 19 deletions (19-Del) or L858R point mutation in exon 21 (21-L858R) remains …
EGFR exon 19 deletions (19-Del) or L858R point mutation in exon 21 (21-L858R) remains …
Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
S Igawa, T Ono, M Kasajima, S Kusuhara… - Investigational New …, 2020 - Springer
Introduction Afatinib is used to treat patients with advanced non-small cell lung cancer
(NSCLC) harboring common EGFR mutations; however, the clinicopathological factors that …
(NSCLC) harboring common EGFR mutations; however, the clinicopathological factors that …
Versorgungsqualität von Tumorpatienten am Lebensende unter Screening-gestützter palliativmedizinischer Mitbetreuung
J Sebeck - 2019 - opus.bibliothek.uni-wuerzburg.de
Im Rahmen des BUKA-Projektes (Beratung und Unterstützung für Patienten mit Krebs und
ihren Angehörigen) wurden im Universitätsklinikum Würzburg Krebspatienten auf …
ihren Angehörigen) wurden im Universitätsklinikum Würzburg Krebspatienten auf …